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Soluble guanylate cyclase (sGC) catalyzes the conversion of gua-
nosine triphosphate into cyclic guanosine-3′,5′-monophosphate, a
key second messenger in cell signaling and tissue homeostasis. It
was recently demonstrated that sGC stimulation is associated with
a marked antiinflammatory effect in the liver of mice with exper-
imental nonalcoholic steatohepatitis (NASH). Here, we investi-
gated the mechanisms underlying the antiinflammatory effect of
the sGC stimulator praliciguat (PRL) in the liver. Therapeutic ad-
ministration of PRL exerted antiinflammatory and antifibrotic ac-
tions in mice with choline-deficient L-amino acid-defined high-fat
diet-induced NASH. The PRL antiinflammatory effect was associ-
ated with lower F4/80- and CX3CR1-positive macrophage infiltra-
tion into the liver in parallel with lower Ly6CHigh- and higher
Ly6CLow-expressing monocytes in peripheral circulation. The PRL
antiinflammatory effect was also associated with suppression of
hepatic levels of interleukin (IL)-1β, NLPR3 (NACHT, LRR, and PYD
domain-containing protein 3), ASC (apoptosis-associated speck-
like protein containing a caspase-recruitment domain), and active
cleaved-caspase-1, which are components of the NLRP3 inflamma-
some. In Kupffer cells challenged with the classical inflammasome
model of lipopolysaccharide plus adenosine triphosphate, PRL
inhibited the priming (expression of Il1b and Nlrp3) and blocked
the release of mature IL-1β. Mechanistically, PRL induced the pro-
tein kinase G (PKG)-mediated phosphorylation of the VASP
(vasodilator-stimulated phosphoprotein) Ser239 residue which, in
turn, reduced nuclear factor-κB (NF-κB) activity and Il1b and Nlrp3
gene transcription. PRL also reduced active cleaved-caspase-1 lev-
els independent of pannexin-1 activity. These data indicate that
sGC stimulation with PRL exerts antiinflammatory actions in the
liver through mechanisms related to a PKG/VASP/NF-κB/NLRP3
inflammasome circuit.
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Nonalcoholic fatty liver disease (NAFLD) is a prevalentcondition affecting roughly 25% of the worldwide pop-
ulation (1). NAFLD is characterized by macrovesicular hepatic
steatosis and its more aggressive form, nonalcoholic steatohe-
patitis (NASH), combines steatosis with inflammation and fi-
brosis (2). Although many molecular pathways contribute to the
development of NASH and the mechanisms leading to the dis-
ease are highly heterogeneous, inflammation appears to play a
crucial role in its progression (1, 2). Moreover, a consistent
target and a satisfactory and effective therapy for this clinical
entity have so far not been achieved.
Recently, we and others have demonstrated that modulation
of cyclic guanosine-3′,5′-monophosphate (cGMP) exerts antiin-
flammatory and antifibrogenic effects in models of NASH and
reduces portal pressure and fibrogenesis in cirrhotic rats (3–5).
In these studies, small molecules with the ability to stimulate
soluble guanylate cyclase (sGC), an enzyme that catalyzes the
conversion of guanosine triphosphate (GTP) to cGMP, proved
to be efficacious in the prevention as well as in the treatment of
hepatic inflammation and fibrosis (3–5). In particular, using an
optimized experimental model of NASH induced by a choline-
deficient L-amino acid-defined high-fat diet (CDAHFD) (6), we
recently demonstrated that administration of the sGC stimulator
praliciguat (PRL) delayed, in a dose-dependent manner, the
development of liver inflammation and fibrosis (3). In addition,
Schwabl et al., using another sGC stimulator (riociguat), de-
scribed reductions in portal hypertension and liver fibrosis in
cholestatic (bile duct ligation) and toxic (carbon tetrachloride;
CCl4) models of cirrhosis in rats (4). More recently, Hall et al.
confirmed the antiinflammatory and antifibrotic effects of PRL
in different murine models of NASH, including CCl4, strepto-
zotocin plus a high-fat/high-cholesterol diet, and thioacetamide
(5). Together, the findings of these studies position the cGMP
pathway as a new and promising therapeutic target for the
pharmacological modulation of the inflammatory and fibrogenic
processes leading to NASH. At present, the sGC stimulator
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riociguat has approval as treatment for pulmonary arterial hy-
pertension and chronic thromboembolic pulmonary hyperten-
sion (7, 8).
There is very limited information on the precise mechanisms
that mediate the liver-protective properties of sGC stimulators.
Hall et al. recently reported that the antifibrotic effects of PRL
in the liver can be ascribed to direct actions of this drug on he-
patic stellate cells (HSCs) (5). In fact, these authors described in
HSCs in culture that PRL has the ability to antagonize the
fibrogenic properties of transforming growth factor-β potentially
through interacting with adenosine monophosphate-activated
protein kinase. and SMAD7 signaling (5). On the other hand,
little is known about the mechanistic aspects linking PRL with its
antiinflammatory actions in the liver. The current study was
undertaken to comprehensively delineate the mechanisms un-
derlying the antiinflammatory effects of PRL in the liver and
included experiments in vivo, in mice with CDAHFD-induced
NASH, and in vitro, in circulating monocytes, resident macro-
phages, Kupffer cells, hepatocytes, and HSCs.
Results
Effects of sGC Stimulation on Whole Body, Organ Weight, and Serum
Biochemistry. Compared with chow-fed mice, mice with
CDAHFD-induced NASH gained less weight across the study
and had a higher liver-to-body weight ratio and lower food intake
(Fig. 1 A–C). There were no changes in white adipose tissue
(WAT)-to-body weight ratio (Fig. 1B). Mice with CDAHFD-
induced NASH also had lower brown adipose tissue (BAT)-to-
body weight and higher spleen-to-body weight ratios (SI Appendix,
Fig. S1A). Mice with CDAHFD-induced NASH exhibited higher
serum aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels (Fig. 1D) together with lower serum
glucose, total cholesterol, and triglyceride (TAG) levels (SI Ap-
pendix, Fig. S1B). The therapeutic administration of the sGC
stimulator PRL to mice with CDAHFD-induced NASH induced
minor changes in the above-described parameters, producing only
a statistically significant decrease in serum ALT levels (Fig. 1D).
This reduction in ALT levels was not seen with the administration
of the farnesoid X receptor (FXR) agonist obeticholic acid
(OCA), which only produced a significant reduction in serum
TAG levels (SI Appendix, Fig. S1B). The sGC stimulator PRL had
a greater concentration in the liver (1,324 ± 355 nM) (mean ± SD)
as compared with serum (27.3 ± 12.3 nM).
Effects of sGC Stimulation on Hepatic Steatosis, Inflammation, and
Fibrosis. As expected, mice with CDAHFD-induced NASH
showed marked hepatic steatosis, inflammation, and fibrosis as
compared with chow-fed mice, as revealed by histological (oil red
O, hematoxylin and eosin [H&E], and sirius red) and immuno-
histochemical (α-smooth muscle actin; α-SMA) staining (Fig. 1 E–
H). In addition, mice with NASH had a higher NAFLD activity
score (NAS), which combines the values of steatosis, inflamma-
tion, and fibrosis (Fig. 1I). The administration of PRL to mice with
CDAHFD-induced NASH was associated with a significant
amelioration of liver injury as demonstrated by significantly lower
oil red O, sirius red, and α-SMA staining and NAS, which includes
H&E staining in its calculation (Fig. 1 E–I). Mice with CDAHFD-
induced NASH receiving OCA showed similar changes in in-
flammation and fibrosis but not in hepatic steatosis (Fig. 1 E–I).
Effects of sGC Stimulation on Hepatic Gene Expression. Since the
liver transcriptome in the NASH model induced by CDAHFD is
poorly characterized, we performed a microarray comparison
between these mice and control chow mice. Fig. 2A shows a
heatmap of the dataset including the 200 genes most differen-
tially regulated, which reveals profound changes in the liver
transcriptome of CDAHFD mice. To reduce the dimension of
this dataset, we performed functional Gene Ontology (GO)
enrichment analysis and identified that a number of cellular
processes were modified during the development of NASH
(Fig. 2B). A deeper insight into this analysis identified that, in
addition to the oxidation–reduction process, inflammation and
innate immune response were two of the top differentially reg-
ulated processes in the liver of mice with CDAHFD-induced
NASH, with an aggregate count of 901 genes listed with a
highly significant P value (Fig. 2B). To further reduce the di-
mension of this analysis, we focused on genes related to in-
flammation, and among them we selected a number of
representative genes that were up-regulated and evenly distrib-
uted across the volcano plot (Fig. 2C). According to these cri-
teria, we assessed the effects of sGC stimulation on the
expression of Tnf, Il1rn, Ccl2, Cxcl10, and Tlr13 by real-time
PCR. As shown in Fig. 2D, administration of PRL to mice
with CDAHFD-induced NASH exerted a generalized inhibition
of the expression of genes coding for cytokines (i.e., Tnf and
Il1rn), chemokines (i.e., Ccl2 and Cxcl10), and receptors that
trigger the innate immune response such as Tlr13. The effects of
OCA on the expression of these inflammatory genes were milder
and only affected the transcription levels of Il1rn, Ccl2, and
Cxcl10 (Fig. 2D), suggesting that sGC stimulation has a broader
and more profound impact on the hepatic inflammatory gene
transcriptome.
Effects of sGC Stimulation on Liver Innate Immune Cells. Since cy-
tokines and chemokines as well as other inflammatory mediators
are mainly produced by innate immune cells, we next explored
the effects of sGC stimulation on liver macrophages, the prin-
cipal immune cell type contributing to NASH in the CDAHFD
model. Livers from mice with CDAHFD-induced NASH had a
more intense F4/80 staining, indicating a higher macrophage
abundance (Fig. 3 A, Upper). Liver sections from these mice also
showed a more extensive staining for C-X3-C motif chemokine
receptor 1 (CX3CR1), which is a marker of infiltrating macro-
phages and monitors the recruitment of monocytes into tissues
(Fig. 3 A, Lower). The quantitative morphometric assessment of
these parameters is shown in Fig. 3B. Administration of PRL to
mice with CDAHFD-induced NASH was associated with signifi-
cantly lower levels of F4/80 signal and a lower percentage of the
area positive for CX3CR1 (Fig. 3 A and B). Changes in CX3CR1
indicated reduced infiltrating monocyte-derived macrophages into
the liver and were consistent with the observation that although
mice with CDAHFD-induced NASH showed a higher number of
circulating monocytes (Ly6C+CD11b+) (Fig. 3C), those receiving
PRL had a lower percentage of monocytes with high expression of
Ly6C (Ly6CHigh) and a larger proportion of these cells with low
expression of this marker (Ly6CLow) (Fig. 3 D and E). This phe-
notypic switch is characteristic of “proresolutive/patrolling” mono-
cytes with less capacity to infiltrate tissues (9), thus indicating that
PRL administration could also limit the infiltration of inflammatory
cells into the injured liver. Of interest, in the microarray dataset,
Ly6c2 and Cx3cr1 were in the list of genes with strong correlations
with the inflammatory process (r = 0.82 and r = 0.74, respectively) in
mice with CDAHFD-induced NASH (SI Appendix, Fig. S2A). The
effects of PRL on the monocyte/macrophage phenotype appeared
not to be exclusive because similar effects were seen with OCA
administration (Fig. 3).
The Antiinflammatory Actions of sGC Stimulation Are Associated with
Inhibition of the NLR Protein 3 Inflammasome in Liver Macrophages.
To investigate whether the antiinflammatory effects of sGC
stimulation could be ascribed to the inhibition of the release of
cytokines by liver macrophages, we next assessed the in vitro
effects of PRL on Kupffer cells, the liver resident macrophages.
In these experiments, Kupffer cells were challenged with the
common proinflammatory stimulus lipopolysaccharide (LPS) in
the presence or absence of PRL, and changes in the expression






















of genes coding for cytokines were assessed by real-time PCR.
Il18 and Il1b, coding for interleukin (IL)-18 and IL-1β, respec-
tively, were the two genes with the largest fold reduction induced
by PRL in Kupffer cells (Fig. 4A). Given that IL-1β and IL-18 are
both processed by the NLRP3 (NACHT, LRR, and PYD
domain-containing protein 3) inflammasome (10–13), these
findings suggested that PRL might exert regulatory actions on
the macrophage inflammasome system. In the microarray data-
set, four genes (i.e., Pycard, Casp1, P2rx7, and Aim2) coding for
inflammasome components were also in the list of genes with
strong correlations with the inflammatory process (between r =
0.79 and r = 0.62) and all of them were up-regulated in mice with
CDAHFD-induced NASH (SI Appendix, Fig. S2).
To test whether PRL can modulate the macrophage inflam-
masome, we then exposed Kupffer cells to LPS plus adenosine
triphosphate (ATP), which is the classical NLRP3 inflammasome
activation model. Messenger RNA (mRNA) expression of Il1b
and Il18 was robustly stimulated by incubation of Kupffer cells
with LPS and ATP, a response that was significantly inhibited in
the presence of PRL (Fig. 4B). Under these conditions, the
cGMP analog 8-Br-cGMP exerted similar inhibitory actions to
those of PRL (Fig. 4C). Consistent with this, the release of
mature IL-1β protein was increased by LPS and ATP and com-
pletely blocked by PRL, as the levels of this cytokine were un-
detectable in the supernatants of PRL-treated Kupffer cells
(Fig. 4D). In contrast, OCA was ineffective in inhibiting Il1b and
Il18 expression (Fig. 4B) and in blocking the secretion of mature
IL-1β (Fig. 4D). PRL inhibition of LPS+ATP-induced mature
IL-1β secretion was similar to that of 8-Br-cGMP (Fig. 4E). The
effects of PRL on the expression of the inflammasome compo-
nents and the release of mature IL-1β were also seen in perito-
neal macrophages exposed to LPS plus ATP (SI Appendix, Fig.
S3A), indicating that the inhibitory actions of PRL on the
inflammasome are not exclusive to liver macrophages. Of note,
PRL appeared to also affect inflammasome assembly, since this
sGC stimulator exerted a comparable inhibitory effect on IL-1β
secretion to that of oridonin, a specific blocker of NLRP3
inflammasome assembly (Fig. 4F).
Fig. 1. Antisteatotic, antiinflammatory, and antifibrotic effects of sGC stimulation with praliciguat in mice with CDAHFD-induced NASH. (A, Left) Body
weight changes during the 12 wk of treatment in mice receiving either chow diet (n = 10), CDAHFD (n = 10), CDAHFD plus PRL at 3 mg/kg (n = 10), or CDAHFD
plus the FXR agonist obeticholic acid at 15 mg/kg (n = 10). (A, Right) Body weight at week 12. (B) Liver and white adipose tissue weights, expressed as tissue/
body weight ratio. (C, Left) Diet intake changes during the 12 wk of treatment in the different groups of mice. (C, Right) Mean diet intake expressed in grams
per mouse per day. (D) Serum AST and ALT levels. (E) Representative photomicrographs (magnification 200×) of liver sections stained with oil red O, H&E,
sirius red, and specific α-SMA antibody. (Scale bars, 50 μm.) (F–H) Histomorphometric analysis of the area stained with oil red O, sirius red, and α-SMA. (I)
NAFLD activity score calculated from the inflammation, steatosis, and fibrosis values as scored by a registered pathologist. Results are expressed as mean ±
SEM. *P < 0.05; **P < 0.005 and ***P < 0.001 vs. chow; aP < 0.05 and bP < 0.001 vs. CDAHFD.










































Fig. 2. Analysis of the liver transcriptome of CDAHFD-fed mice. Effects of PRL on the expression of inflammatory genes. (A) Heatmap showing the top 200
differentially regulated genes ranked by fold change (up-regulated, red; down-regulated, green) in the liver from CDAHFD-fed mice (n = 8) in comparison
with chow-fed mice (n = 8). (B, Upper) Gene Ontology database (http://www.geneontology.org) functional classification of GO enrichment in liver of
CDAHFD-fed mice in comparison with chow. (B, Lower) List of top GO terms in the database ranked by count and P value. (C) Volcano plot representing a
number of selected genes up-regulated in CDAHFD and evenly distributed in the plot. (D) Expression of Tnf, Il1rn, Ccl2, Cxcl10, and Tlr13 in liver samples from
the animals included in the different groups of the study as determined by real-time PCR. Results are expressed as mean ± SEM. *P < 0.001 vs. chow; aP < 0.05,
bP < 0.005, and cP < 0.001 vs. CDAHFD.






















To translate these findings to in vivo conditions, we next assessed
the expression at the protein level of the inflammasome components
NLRP3, pro-caspase-1 (Pro-Casp-1), cleaved-caspase-1 (c-Casp-1),
pro-IL-1β, IL-1β (mature), and ASC (apoptosis-associated speck-like
protein containing a caspase-recruitment domain) in livers of mice
with CDAHFD-induced NASH treated with PRL. As shown in
Fig. 4G, mice with CDAHFD-induced NASH had increased protein
levels of the inflammasome components in the liver, while mice
treated with PRL did not. Densitometric analysis of the bands is
shown in SI Appendix, Fig. S3B. Importantly, PRL decreased the
protein levels of the active form of caspase-1 (c-Casp-1), which is
cleaved after the assembly of the inflammasome (Fig. 4G), supporting
the finding with oridonin and the view that PRL not only inhibits
priming but also might interfere with inflammasome assembly. Re-
duction of the hepatic levels of IL-1β in mice with CDAHFD-
induced NASH receiving PRL further solidified these findings
(Fig. 4H). Similar to that observed in vitro, OCA treatment in mice
with CDAHFD-induced NASH did not modify the protein levels of
the inflammasome components, especially those that are critical for
its functioning such as active c-Casp-1 and mature IL-1β (Fig. 4 G
andH and SI Appendix, Fig. S3B). The lack of effects of OCA on the
NLRP3 inflammasome was not due to improper activation of FXR
since OCA induced the expression ofAbcb11, a bona fide FXR target
gene that codes for the bile salt export pump (SI Appendix, Fig. S4).
Modulation of the NLRP3 Inflammasome by PRL in Kupffer Cells Is
Mediated by VASP Phosphorylation and NF-κB Inhibition. To inves-
tigate the mechanisms by which PRL modulates the macrophage
NLRP3 inflammasome, we dissected the potential pathways
linking cGMP signaling with the priming (first hit) and assembly
or activation (second hit) of the inflammasome complex in
Kupffer cells. We first explored the canonical cGMP signal
transduction pathway implicating protein kinase G1 (PKG1) and
the phosphorylation of its downstream effector vasodilator-
stimulated phosphoprotein (VASP). As shown in Fig. 5A, incu-
bation of Kupffer cells with PRL during the activation of the
inflammasome with LPS + ATP was associated with no changes
in PKG1 protein levels but increased VASP Ser239 phosphory-
lation and decreased LPS+ATP-induced NF-κB inhibitor alpha
(IKB-α) phosphorylation, indicative of reduced nuclear factor-
κB (NF-κB) activity. Since NF-κB is a major driver of inflam-
matory gene expression, inhibition of NF-κB activity by PRL was
consistent with reductions in the expression of downstream tar-
get genes such as Nlrp3 (Fig. 5B) and Il1b and Il18 (Fig. 4B). To
further support our findings on VASP and IKB-α phosphoryla-
tion, experiments were repeated and reproduced in Kupffer cells
stimulated with LPS for a shorter time (30 min) (SI Appendix,
Fig. S5A). The phosphorylation of VASP and inhibition of NF-
κB in response to PRL were also clearly confirmed in vivo as
VASP phosphorylation was higher and IKB-α phosphorylation
was lower in livers from mice with CDAHFD-induced NASH
receiving PRL than in livers from CDAHFD controls (Fig. 5C).
Although we did not observe changes in the protein levels of
PKG1, the involvement of this kinase in PRL inhibition of the
NLRP3 inflammasome-mediated IL-1β secretion was confirmed
by performing concentration–response experiments with the
PKG-blocking agent Rp-8-Br-PET-cGMPS (Rp-8-Br) in which
efficacy was observed at 30 μM concentration (Fig. 5D).
Fig. 3. Effects of PRL on liver and peripheral blood monocytes. (A) Representative photomicrographs (magnification 200×) of liver sections stained with
specific F4/80 and CX3CR1 antibodies used for the assessment of total liver macrophages and infiltrated liver macrophages, respectively. (Scale bars, 50 μm.)
(B) Histomorphometric analysis of the area stained with F4/80 and CX3CR1 antibodies. (C) Percentage of total monocytes in the peripheral blood of mice
determined by flow cytometry (n = 4 for each group). (D) Percentage of Ly6CHigh and Ly6CLow monocytes among the Ly6C+Cd11b+ cells. (E) Representative
flow cytometry plots for Ly6C-expressing monocytes. Results are expressed as mean ± SEM. *P < 0.05; **P < 0.005 and ***P < 0.001 vs. chow; aP < 0.05, bP <
0.005, and cP < 0.001 vs. CDAHFD.










































Furthermore, blockage of PKG with Rp-8-Br prevented PRL
induction of VASP phosphorylation and reduction of IKB-α
phosphorylation, confirming that PRL actions were mediated by
this kinase (Fig. 5E and SI Appendix, Fig. S5A). To further
confirm the involvement of PKG in PRL actions, we performed
knockdown experiments using a small interfering RNA (siRNA)
directed against Prkg1, the gene encoding for PKG1. As shown in
Fig. 5F, protein expression for PKG1 was significantly reduced
72 h after siRNA transfection, an effect that was associated with
the loss of the ability of PRL to inhibit LPS+ATP-induced IL-1β
secretion.
We next explored mechanisms by which PRL might interfere
with the second hit leading to the oligomerization of the inactive
inflammasome complex (NLRP3, ASC, and Casp-1) and the
processing of mature IL-1β. A potential mechanism that could
link the cGMP pathway to inhibition of the NLRP3 inflamma-
some is pannexin-1, a hemichannel protein that interacts with the
ATP receptor P2X7 to allow inflammasome assembly during
LPS + ATP challenge (14–16). To explore this possibility, we
incubated Kupffer cells with LPS + ATP and the selective
pannexin-1 mimetic inhibitory peptide 10Panx1 or its control
scrambled peptide. The presence of 10Panx1 in the Kupffer cell
media did not modify the inhibitory actions of PRL on the ex-
pression of Il1b, Il18, and Nlrp3 (SI Appendix, Fig. S5 B–D) as
well as on the secretion of mature IL-1β (SI Appendix, Fig. S5E),
excluding the involvement of pannexin-1 in PRL inhibition of the
NLRP3 inflammasome.
Participation of Other Liver Cell Types in Inflammasome-Mediated
Release of IL-1β. Hepatocytes are also able to produce mature
IL-1β through the NLRP3 inflammasome complex (17), espe-
cially when these cells are exposed to inflammatory stimuli such
as LPS (18). Indeed, we were able to induce the expression of
Il1b, Il18, and Nlrp3 (Fig. 6A) and to trigger the secretion of
mature IL-1β (Fig. 6B) by incubating murine hepatocytes with
LPS plus ATP. On a per-cell basis, the release of mature IL-1β
by hepatocytes was comparable with that of HSCs and lower than
its release by Kupffer cells (Fig. 6B). In hepatocytes, PRL also
down-regulated the expression of Il1b, Il18, and Nlrp3 (Fig. 6A)
and reduced IL-1β secretion (Fig. 6B), although its inhibitory
Fig. 4. Antiinflammatory actions of PRL are associated with inhibition of the NLRP3 inflammasome. (A) Fold reduction in the expression of inflammatory
genes induced by the addition of PRL to incubations of Kupffer cells exposed to LPS. (B) Il1b and Il18 mRNA expression in isolated Kupffer cells challenged
with LPS + ATP and treated with PRL or OCA. (C) Il1b and Il18mRNA expression in isolated Kupffer cells challenged with LPS + ATP and treated with PRL or the
cGMP analog 8-Br-cGMP. (D) IL-1β levels in supernatants of Kupffer cells from B as determined by ELISA. (E) IL-1β levels in supernatants of Kupffer cells from C.
(F) IL-1β levels in supernatants of Kupffer cells challenged with LPS + ATP and treated with PRL or the NLRP3 inflammasome inhibitor oridonin. (G) NLRP3,
pro-caspase-1, cleaved-caspase-1, pro-IL-1β, IL-1β, ASC, and β-actin protein levels in liver tissue from the mice included in the four groups of the study as
determined by SDS/PAGE Western blot. (H) IL-1β levels in the liver relative to the DNA content. Results are expressed as mean ± SEM of n = 4 separate
experiments. *P < 0.05 and **P < 0.001 vs. chow or vehicle; aP < 0.05, bP < 0.005, and cP < 0.001 vs. CDAHFD or LPS + ATP. ND, not detectable.






















effect was more modest than in Kupffer cells, in which PRL
completely suppressed LPS+ATP-induced IL-1β secretion. Of
interest, the expression of Prkg1 and Prkg2, the genes encoding
for PKG1 and PKG2, was marginal in hepatocytes as compared
with Kupffer cells (Fig. 6C).
We next assessed the expression in hepatocytes of Gucy1a3,
Gucy1a2, Gucy1b3, and Gucy1b2, which encode for the soluble
guanylate cyclase α1, α2, β1, and β2 subunits, respectively. As
shown in Fig. 6D, as compared with Kupffer cells and HSCs,
expression of Gucy1a3, Gucy1a2, and Gucy1b3 was marginal in
hepatocytes, whereas the expression of Gucy1b2, encoding for
the β2-subunit of sGC, which has been reported to produce
cGMP in its homomeric configuration (19), was detected in
hepatocytes but not in Kupffer cells or HSCs (Fig. 6D). Inter-
estingly, PRL stimulation of Kupffer cells and HSCs resulted in
the up-regulation of the α1-, α2-, and β1-subunits (i.e., Gucy1a3,
Gucy1a2, and Gucy1b3) whereas the β2-subunit (i.e., Gucy1b2)
was the only isoform up-regulated during the incubation of he-
patocytes with PRL (SI Appendix, Fig. S6A). The expression of
Gucy1b2 in hepatocytes was confirmed at the protein level by
immunocytochemistry (see the positive signal for binucleated
cells in Fig. 6E). To confirm that the effect of PRL on IL-1β
secretion was not reflecting the presence of contaminating
Kupffer cells and/or HSCs in the hepatocyte cultures, we tested
the expression of specific markers for the different liver cell
types, as previously described by others (17). As shown in Fig. 6F,
cultures of hepatocytes predominantly expressed the albumin
gene (Alb) and were virtually negative for the expression of
Adgre1 (coding for F4/80, a specific macrophage marker) and
Gfap (a specific marker for HSCs). The percentage of contam-
inating Kupffer cells and HSCs in hepatocyte cultures was
quantitated by flow cytometry, resulting in less than 0.7% of
Kupffer cells and 7.6% of vitamin A-positive cells (mostly HSCs)
(Fig. 6G). To further minimize the involvement of contaminating
HSCs in our findings, we incubated hepatocytes with gliotoxin,
which specifically depletes HSCs without affecting hepatocyte
viability (20). As shown in Fig. 6H, the inhibitory effect of PRL
on hepatocyte LPS+ATP-induced Il1b expression and IL-1β
secretion was not affected by gliotoxin, despite this toxin signif-
icantly depleting the HSC population (SI Appendix, Fig. S6B).
NLRP3 Inflammasome Blockade by sGC Stimulation in Hepatocytes Is
Also Mediated by VASP Phosphorylation and NF-κB Inhibition. Simi-
lar to that observed in Kupffer cells, PRL induced VASP phos-
phorylation and markedly reduced IKB-α phosphorylation in
hepatocytes challenged with the classical inflammasome activa-
tion model of LPS plus ATP (Fig. 7A). These effects were
blocked by the PKG blocker Rp-8-Br (Fig. 7B) and were
reproduced in hepatocytes stimulated with LPS for a shorter
time (30 min) (SI Appendix, Fig. S6C). Consistent with this, Rp-
8-Br blocked PRL-induced down-regulation of Il1b, Il18, and
Nlrp3 expression (Fig. 7C) and suppressed the PRL-induced
reduction of IL-1β secretion by hepatocytes (Fig. 7D). More-
over, the reduction in inflammasome priming was similar in
PRL-treated hepatocytes to those treated with the cGMP analog
8-Br-cGMP (Fig. 7E). Finally, the reduction in IL-1β secretion in
response to PRL was similar to the reduction exerted by
8-Br-cGMP and oridonin (Fig. 7F).
Fig. 5. PRL blocks the NLRP3 inflammasome in Kupffer cells through mechanisms based on VASP phosphorylation and NF-κB inhibition. (A, Left) PKG1,
phospho-VASP (Ser239) (P-VASP), VASP, phospho-IKB-α (P-IKB-α), IKB-α, and β-actin protein levels in Kupffer cells challenged with LPS + ATP alone or in the
presence of PRL. (A, Right) Densitometric analysis of the P-VASP/VASP and P-IKB-α/IKB-α ratios. (B) Nlrp3 mRNA expression in Kupffer cells incubated in the
conditions described in A. (C, Left) PKG1, P-VASP (Ser239), VASP, P-IKB-α, IKB-α, and β-actin protein levels in liver tissue from the mice included in the four
groups of the study. (C, Right) Densitometric analysis of the P-VASP/VASP and P-IKB-α/IKB-α ratios. (D) Levels of mature IL-1β in supernatants from Kupffer cells
challenged with LPS + ATP and treated with PRL in the presence or absence of the PKG-blocking agent Rp-8-Br at 0.6 and 30 μM concentrations. (E, Left) PKG1,
P-VASP (Ser239), VASP, P-IKB-α, IKB-α ,and β-actin protein levels in Kupffer cells challenged with LPS + ATP and treated with PRL in the presence or absence of
Rp-8-Br. (E, Right) Densitometric analysis of the P-VASP/VASP and P-IKB-α/IKB-α ratios. (F, Left) PKG1 and β-actin protein levels in Kupffer cells incubated with
vehicle (Veh) and LPS + ATP alone or in combination with PRL, PRL plus scrambled nontargeting RNA (scRNA), and PRL plus siRNA targeting the Prkg1 gene. (F,
Right) IL-1β levels in supernatants of Kupffer cells incubated under these conditions. Results are expressed as mean ± SEM of n = 3 or 4 separate experiments.
*P < 0.05 and **P < 0.001 vs. chow or vehicle; aP < 0.05 and bP < 0.005 vs. CDAHFD or LPS + ATP. ns, not statistically significant vs. LPS + ATP.











































This study describes a mechanism by which sGC stimulators
modulate liver inflammation in an experimental model of
NASH: inhibition of NLRP3 inflammasome-mediated IL-1β
production. The involvement of IL-1β in the progression of liver
injury and evidence that IL-1 receptor-deficient mice are pro-
tected from liver damage have previously been demonstrated
(21, 22). Evidence that NLRP3 inflammasome activation is re-
quired for development of liver inflammation and fibrosis in
NASH has also been provided (23). Therefore, our study con-
tributes to the understanding of the antiinflammatory actions
associated with the stimulation of sGC with PRL in experimental
NASH, which, together with its antisteatotic and antifibrogenic
effects, supports further investigation of PRL in the prevention
and treatment of chronic liver diseases. Other important aspects
of our study are the following: 1) We used a therapeutic ap-
proach in which the administration of PRL was initiated after
appearance of the first signs of NASH development in mice,
extending results from a previous investigation administering
PRL in a preventive mode (3); 2) our study directly compared
the therapeutic effects of PRL with those of the FXR agonist
OCA, the only drug with a good clinical profile in patients with
NAFLD (24); and 3) our study comprises a systematic analysis of
the expression of the different sGC subunits in individual liver
cell types, including liver resident macrophages, hepatocytes,
and HSCs.
IL-1β is one of the most potent proinflammatory cytokines and
plays a critical role in the so-called cytokine storm, a descriptor
of the dramatic consequences of the massive release of cytokines
during uncontrolled inflammation (10). Unlike many other cy-
tokines, IL-1β is produced via nonconventional multiprotein
complexes called inflammasomes, which are required for the
posttranslational processing of an inactive 31-kDa precursor,
termed pro-IL-1β, into mature IL-1β (11). Inflammasomes also
process the maturation of pro-IL-18 into mature IL-18 (11, 12).
The most well characterized inflammasome is the NLRP3
inflammasome, which is assembled when NLRP3 homotypically
engages ASC to recruit the inactive zymogen pro-Casp-1
(11–13). Oligomerization of pro-Casp-1 proteins induces their
autoproteolytic cleavage into active cleaved-Casp-1, a cysteine-
dependent protease that cleaves pro-IL-1β and pro-IL-18 to
generate the biologically active inflammatory cytokines IL-1β
and IL-18, respectively (11–13). Commonly, the activation of the
NLRP3 inflammasome is the result of a two-step process
Fig. 6. Participation of other liver cell types in inflammasome-mediated release of IL-1β. (A) Il1b, Il18, and Nlrp3 mRNA expression in isolated hepatocytes
exposed to LPS + ATP and treated with PRL. (B) Comparison of the IL-1β levels in the supernatants of hepatocytes (HPCs), Kupffer cells (KCs), and hepatic
stellate cells challenged with LPS + ATP and treated with PRL. (C) Expression of Prkg1 and Prkg2 in resting HPCs and KCs. (D) Expression of Gucy1a3, Gucy1a2,
Gucy1b3, and Gucy1b2 in resting HPCs, KCs, and HSCs. (E) Representative photomicrographs of isolated HPCs stained with a specific GUCY1B2 antibody. (E,
Left) Magnification 40×. (Scale bar, 200 μm.) (E, Right) Magnification 200×. (Scale bar, 50 μm.) (F) Expression of Alb, Adgre1, and Gfap in KCs, HSCs, and HPCs.
(G) Representative flow cytometry plots for KCs (F4/80+Cd11b+; 0.62 ± 0.09% of total cells) (Upper) and HSCs (vitamin A+; 7.62 ± 0.64% of total cells) (Lower)
present in HPC isolations. (H) Il1b mRNA expression and levels of mature IL-1β in the supernatants of HPCs challenged with LPS + ATP and treated with PRL in
the presence or absence of gliotoxin. Results are expressed as mean ± SEM of n = 3 or 4 separate experiments. *P < 0.05; **P < 0.005 and ***P < 0.001 vs.
vehicle; aP < 0.05 and bP < 0.005 vs. LPS + ATP; #P < 0.005 and ##P < 0.001 vs. HPCs.






















Fig. 7. Inhibition of the NLRP3 inflammasome by PRL in hepatocytes is also mediated by VASP phosphorylation and NF-κB inhibition. (A, Left) PKG1, P-VASP
(Ser239), VASP, P-IKB-α, IKB-α, and β-actin protein levels in hepatocytes challenged with LPS + ATP and treated with PRL. (A, Right) Densitometric analysis of
the P-VASP/VASP and P-IKB-α/IKB-α ratios. (B, Left) PKG1, P-VASP (Ser239), VASP, P-IKB-α, IKB-α, and β-actin protein levels in hepatocytes challenged with LPS +
ATP in the presence or absence of the PKG antagonist Rp-8-Br and treated with PRL. (B, Right) Densitometric analysis of the P-VASP/VASP and P-IKB-α/IKB-α
ratios. (C) Expression of Il1b, Il18, and Nlrp3 in isolated hepatocytes challenged with LPS + ATP in the presence or absence of Rp-8-Br and treated with PRL. (D)
IL-1β levels in the supernatants from hepatocytes incubated with LPS + ATP and treated with PRL in the presence or absence of Rp-8-Br at 0.6 and 30 μM
concentrations. (E) Il1b mRNA expression in isolated Kupffer cells challenged with LPS + ATP and treated with PRL or the cGMP analog 8-Br-cGMP. (F) IL-1β
levels in the supernatants from Kupffer cells challenged with LPS + ATP and treated with PRL, 8-Br-cGMP, or the NLRP3 inflammasome inhibitor oridonin.
Results are expressed as mean ± SEM of n = 3 or 4 separate experiments. *P < 0.05; **P < 0.005 and ***P < 0.001 vs. vehicle; aP < 0.05 and bP < 0.005 vs.
LPS + ATP.










































referred to as priming and assembly. The first step is the priming
signal triggered by Toll-like receptor (TLR) ligands such as LPS,
which leads to the transcriptional up-regulation of pro-IL-1β and
NLRP3, whereas the second step implicates the assembly of the
inflammasome components (i.e., NLRP3, ASC, and pro-Casp-1),
a process that can be triggered by different stimuli such as ATP
(11–13). Our data provide evidence that PRL inhibits IL-1β se-
cretion by regulating both processes, thus providing an approach
to reversing the adverse effects of IL-1β that is complementary to
the use of monoclonal antibodies such as canakinumab, which
blocks the binding of IL-1β to its receptor [see results from the
CANTOS Trial (25)].
Our study also provides data toward elucidating the mechanism
underlying the inhibition of the priming of the hepatic NLRP3
inflammasome by PRL. These findings are schematically illustrated
in Fig. 8 and support the view that the down-regulation of the ex-
pression of pro-IL-1β and NLRP3 in Kupffer cells by PRL is as-
sociated with reduced phospho-IKB-α, and thus with NF-κB
inhibition. These results are in agreement with a recent study by
Hall et al. reporting a reduction of CCl4-induced hepatic inflam-
mation in rats receiving PRL, an effect that was accompanied by a
decrease in the protein levels of p65/NF-κB (5). Of interest, in our
study, inhibition of NF-κB by PRL was associated with increased
VASP Ser239 phosphorylation, which is a well-stablished down-
stream target of cGMP-dependent kinases and plays a crucial role
in the antiinflammatory signaling of sGC (26, 27). These findings
are consistent with those reported by Tateya et al., who demon-
strated that Kupffer cells from VASP-deficient mice had increased
NF-κB activation and that the cGMP analog 8-Br-cGMP was not
able to exhibit antiinflammatory effects in cells lacking VASP ex-
pression (27). At present, the connection between VASP phos-
phorylation and NF-κB inhibition awaits further investigation.
PRL produced a marked reduction of the active form of
caspase-1 (cleaved-caspase-1), the formation of which requires the
assembly of the inflammasome. Of interest, PRL exerted a com-
parable inhibitory effect on IL-1β secretion with that of oridonin, a
specific blocker of the NLRP3 inflammasome assembly. These
findings are in agreement with previous work by Kim and col-
laborators demonstrating that nitric oxide (NO) can suppress
caspase-1 cleavage and IL-1β and IL-18 release in macrophages
(28). Investigation of the mechanisms underlying the reduction of
inflammasome assembly induced by PRL revealed that it was not
mediated by pannexin-1, since inhibition of this hemichannel did
not modify PRL actions. This finding does not support previous
data in human and murine cell lines showing that the blockage of
pannexin-1 was associated with inhibition of caspase-1 cleavage
and IL-1β processing (15), but are in agreement with data in
primary macrophages from pannexin-1 knockout mice, which still
have the ability to release IL-1β (29).
Our data indicate that the primary cell target of PRL antiin-
flammatory effects in the liver is resident (i.e., Kupffer cells) and/
or infiltrated macrophages, although hepatocytes might also
contribute to PRL actions. This view is supported by the obser-
vation that PRL completely suppressed IL-1β secretion in
Kupffer cells, whereas its inhibitory effect was more modest in
hepatocytes. This difference could be due to the fact that
Kupffer cells showed considerably higher expression of Prkg1
(∼100 times) and Prkg2 (∼10 times) than hepatocytes. Since
Prkg1 and Prkg2 encode for the two PKG isoforms that effec-
tively mediate cGMP signaling, increased content of PKG likely
translates into higher inhibition of the NLRP3 inflammasome by
PRL. In any event, hepatocytes are sensitive to inflammatory
stimuli such as LPS and the saturated fatty acid palmitic acid, and
release IL-1β secondary to NLRP3 inflammasome activation (17,
Fig. 8. Schematic illustration summarizing the potential mechanisms of action of sGC stimulation in Kupffer cells.






















18). Moreover, these cells have the ability to respond to NO with
increased cGMP production as reported by Wood and Ignarro (30)
in liver slices and by Billiar et al. (31) in isolated hepatocytes.
However, the expression of sGC in hepatocytes remains contro-
versial. Hall et al. previously reported that these cells are negative
for sGCα1 and sGCβ1 (5). On the other hand, Gobeil and collab-
orators demonstrated constitutive localization of sGC in cytoplasmic
and nuclear spaces in rat hepatocytes by in situ cryoimmunogold
electron microscopy (32). In our study, we detected marginal ex-
pression of the genes encoding for the sGCα1-, sGCα2-, and sGCβ1-
subunits in hepatocytes but positive expression at both mRNA and
protein levels of the sGCβ2-subunit, which according to Koglin et al.
is able to produce cGMP in its homomeric configuration (19). One
might argue that inhibition of IL-1β secretion by PRL in hepatocytes
could reflect the presence of contaminating Kupffer cells or HSCs.
However, our hepatocyte cultures contained less than 0.7% of
Kupffer cells and about 7.6% of HSCs. Furthermore, depletion of
HSCs with gliotoxin in our hepatocyte incubations did not signifi-
cantly modify the inhibitory actions of PRL on IL-1β secretion.
Therefore, we propose that inhibitory effects of PRL on IL-1β se-
cretion by hepatocyte cultures are mediated by direct actions of PRL
on these parenchymal liver cells.
In summary, our study provides evidence that the adminis-
tration of the sGC stimulator PRL to mice with experimentally
induced NASH exerts antiinflammatory actions in the liver,
mainly in Kupffer cells, through inhibition of NLRP3 inflam-
masome priming and activation. In liver cells, the inhibitory ac-
tions of PRL on NLRP3 inflammasome priming appeared to be
mediated by the interaction of cGMP with the PKG/VASP/NF-
κB pathway, whereas the effects on NLRP3 inflammasome ac-
tivation appeared to be mediated through cleaved-caspase-1 in-
hibition. This study provides insights into the mechanisms of
action of sGC stimulators at the experimental level in NASH.
Future investigations in patients with NASH to further explore
the clinical relevance of our findings are warranted.
Materials and Methods
Animals and Experimental Design. Male C57BL/6J mice were randomly
assigned to four independent groups, which received the following treat-
ments: 1) control chow diet (n = 10) for 12 wk; 2) CDAHFD (60% kcal from
fat) (n = 10) for 12 wk; 3) CDAHFD diet for 3 wk and then CDAHFD sup-
plemented with the sGC stimulator PRL (3 mg·kg−1·d−1) (n = 10) for 9 more
weeks; and 4) CDAHFD for 3 wk followed by CDAHFD plus the FXR agonist
OCA (15 mg·kg−1·d−1) (n = 10) for 9 more weeks. See SI Appendix for more
details. All studies were conducted in accordance with the criteria of the
Investigation and Ethics Committee of the Universitat de Barcelona and the
European Community laws governing the use of experimental animals.
Isolation of Primary Liver Cells. Hepatocytes, Kupffer cells, and HSCs were
isolated from C57BL/6J mice (n = 56) by a three-step in situ collagenase
perfusion through the portal vein. After pelleting the hepatocytes, Kupffer
cells and HSCs were isolated by centrifugation using 16 and 14% density
Nycodenz gradients, respectively (SI Appendix).
Isolation of Peritoneal Macrophages. Peritoneal exudates from C57BL/6J mice
(n = 8) were collected by peritoneal lavage with 7 mL of ice-cold Dulbecco’s
phosphate-buffered saline−/− and peritoneal macrophages were isolated by
adhesion in a humidified 5% CO2 incubator at 37 °C for 2 h (SI Appendix).
Cell Incubations. Hepatocytes, Kupffer cells, HSCs, and peritoneal macro-
phages were seeded in 12-well plates and exposed to LPS (100 ng/mL) for
30 min followed by treatment with either vehicle, PRL (10 μM), or OCA (2 μM)
(Selleckchem) for 3 h, 30 min at 37 °C before the addition of ATP (5 mM) for
1 h. For mechanistic experiments, cells were pretreated with the PKG blocker
Rp-8-Br (0.6 to 30 μM) (Tocris). In additional experiments, Kupffer cells were
incubated with Accell mouse Prkg1 siRNA or scrambled nontargeting RNA (1
μM) (Horizon Discovery) for 72 h followed by LPS + ATP treatment in the
presence or absence of PRL. In some experiments, cells were treated with the
NLRP3 inflammasome blocker oridonin (2 μM) (Tocris) or the cGMP analog
8-Br-cGMP (50 μM) (Sigma-Aldrich) instead of PRL. In another set of exper-
iments, cells were pretreated with the pannexin-1 inhibitory peptide
10Panx1 trifluoroacetate salt (100 μM) or the control scrambled peptide
10Panx1 trifluoroacetate salt (100 μM), both from Sigma-Aldrich. For the
depletion of HSCs in hepatocyte cultures, we pretreated the hepatocytes
with gliotoxin (1.5 μM) (Sigma-Aldrich) followed by the LPS + ATP treatment
in the presence or absence of PRL.
Biochemical Analyses and Measurement of Cytokine Levels. Serum concen-
trations of glucose, total cholesterol, TAG, AST, and ALT were determined by
standard laboratory procedures. Levels of IL-1β in liver tissue were assessed in
a Luminex 100 System using a custom-made MILLIPLEX MAP Mouse High
Sensitivity T Cell Magnetic Bead Panel (Merck Millipore). IL-1β levels in cell
supernatants were assessed by enzyme-linked immunosorbent assay (ELISA)
(Beckton Dickinson) (SI Appendix).
Liver and Serum Levels of PRL and OCA. Drug levels in liver tissue and serum
samples were analyzed by liquid chromatography-tandemmass spectrometry
in positive-ion–mode electrospray ionization (SI Appendix).
Histological Analysis of Liver Steatosis, Inflammation, and Fibrosis. Steatosis
was assessed by oil red O staining of OCT-embedded cryosections, and in-
flammatory injury was scored by analyzing the amount of inflammatory foci/
fields in H&E-stained sections and fibrosis by sirius red staining (SI Appendix).
Immunohistochemistry and Immunocytochemistry. Immunostainings for F4/80,
α-SMA, and CX3CR1 were performed using primary species-specific anti-
bodies developed with diaminobenzidine, visualized at 200×, and quantified
by histomorphometry. Hepatocytes seeded on collagen I-coated eight-well
Lab-Tek slides (5 × 104 cells per well) were immunostained with primary
rabbit anti-mouse GUCY1B2 antibody (LS-C383668; 1:200; LSBio), developed
with diaminobenzidine, and counterstained with hematoxylin (SI Appendix).
Flow Cytometry Analysis. For the analysis of peripheral blood monocytes and
Cd45+Cd11b+Ly6C+ cells, Ly6CHigh and Ly6CLow subpopulation blood (100 μL)
was extracted from mouse tail vein and a total of 6 × 105 white blood cells
were incubated with APC anti-mouse CD11b (Thermo Fisher Scientific),
fluorescein isothiocyanate anti-mouse Ly6C (BioLegend), and V450 anti-
mouse CD45.2 (Beckton Dickinson) for 20 min at 4 °C in the dark. For the
analysis of Kupffer cells in hepatocyte cultures, a total of 106 hepatic cells
were incubated with APC anti-mouse CD11b and PE anti-mouse F4/80
(eBioscience) for 20 min at 4 °C in the dark. HSCs were discriminated by vi-
tamin A autofluorescence. Analysis was performed on a BD LSRFortessa
cytometer using BD FACSDiva software (SI Appendix).
DNA Extraction and Quantification. Genomic DNA from liver tissue was isolated
using the Omni-Pure Tissue Genomic DNA Purification System (Gene Link) and
its concentration was assessed on a NanoDrop 1000 spectrophotometer
(NanoDrop Technologies).
Gene Expression Analysis by Real-Time PCR. Isolation of total RNA was per-
formed using TRIzol reagent (MRC), complementary DNA (cDNA) synthesis
was performed using the High-Capacity cDNA Archive Kit (Applied Bio-
systems), and real-time PCR quantification was performed using validated
and predesigned TaqMan Gene Expression Assays on a 7900HT Fast System
(Applied Biosystems) (SI Appendix).
Microarray Analysis. Processing of RNA samples, fragmentation, and labeling
of single-stranded cDNA were performed according to the Affymetrix WT
PLUS Reagent Kit user guide on an automated system (Beckman FX robot).
Following fragmentation and terminal labeling, single-stranded cDNAs were
hybridized for 17 h at 45 °C on Clariom S Array Plate Mouse 24, using the
automated GeneTitan System. See SI Appendix for details on normalization
and analysis of microarray data.
Analysis of Protein Expression by Western Blot. Extracted total proteins were
separated for 90 min at 120 V at 4 °C by 10% sodium dodecyl sulfate/poly-
acrylamide gel electrophoresis (SDS/PAGE). Transfer onto polyvinylidene
difluoride membranes was performed by the iBlot Dry Blotting System
(Invitrogen) and membranes were incubated overnight at 4 °C with primary
species-specific antibodies. Bands were visualized using the EZ-ECL Chem-
iluminescence Detection Kit (Biological Industries) on an LAS 4000 Imaging
System (GE Healthcare Life Sciences) and quantified using Image GE
ImageQuant TL analysis software. See SI Appendix for more details.










































Statistical Analysis. Statistical analysis was performed with Prism version 8.0
(GraphPad Software). For multiple comparisons, an ANOVA of the data in
which a significant (P < 0.05) main effect followed by Dunnett’s post hoc test
was performed. For single comparisons, Student’s unpaired t test was used.
Results are expressed as mean ± SEM. All measurements were undertaken in
at least two technical replicates.
Data Availability. The microarray gene expression data reported in this article
have been deposited in the Gene Expression Omnibus (accession no.
GSE154892). All study data are included in the article and SI Appendix.
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